Sun Pharma Q1 Review: Brokerages Back India Growth, Flag Specialty Slowdown
Macquarie and HSBC remained positive on Sun Pharma after June-quarter EBITDA and margins beat estimates, while BofA flagged slowing US and specialty sales and limited near-term catalysts.
\